What this site is
SR17.org is an independent, science-based reference on the experimental compound SR-17018. It synthesizes peer-reviewed scientific literature, regulatory information, and publicly reported community observations. It is updated as new data becomes available.
It is intended for informational and educational use only. It is not medical, legal, or treatment advice. SR-17018 has not been formally studied in humans; statements about its effects in people are inherently provisional.
Editorial principles
- Hierarchy of evidence.Peer-reviewed clinical trials > peer-reviewed animal studies > regulatory/forensic body publications > expert-published reviews > self-reported community observations. Each is labeled in the text.
- Conflict transparency. Where studies disagree (as is currently the case for several aspects of SR-17018 pharmacology), the conflict is described, not resolved by editorial choice.
- No advocacy. This site does not advocate for or against SR-17018 use. It does not recommend dosing protocols. It describes what is known, what is reported, and what is unknown.
- Source linking. Every factual claim is traceable to a source listed in the bibliography. Adding new content requires adding the source.
- Date stamping. Material edits include a changelog entry with date and section.
Editorial team
SR17.org is maintained by an editorial team and a roster of named contributors. Editor and contributor profiles — with credentials, affiliations, and any disclosures — will be published on this page as the contributor list stabilizes. Where a page has been reviewed by a clinician, pharmacologist, or analytical chemist, that reviewer is named in the page's review history.
- Lead editor — to be named on launch of the v1 byline.
- Medical reviewer — clinician credentialed in addiction medicine; review log per page in development.
- Analytical reviewer — for the testing program and any chromatography content.
- Legal counsel — for the legal-status, disclaimer, and compliance content.
Contributor identities, credentials, and any conflicts of interest will be published with the v1 byline release. Until then, all content reflects review by the maintainer team and external sources cited.
Conflicts of interest
- SR17.org accepts no funding, sponsorship, or in-kind support from vendors, distributors, or marketplaces of SR-17018 or any related compound.
- SR17.org runs no advertising and operates no affiliate links.
- The lab-testing program is funded by editorial reserves and donations; it does not test for, advertise, or otherwise promote any vendor — including vendors whose product receives a clean test.
- Editors and contributors must disclose any consulting relationships, employment, equity, or grant relationships in the opioid pharmacology, treatment, or harm-reduction space. Disclosures are published with the contribution.
- Generative-AI tools are used for code maintenance, layout drafting, and copy review. AI is not used as a citable source for any factual statement; primary sources and human review are required for publication.
Contributing
The site is open-source. Tips, corrections, and new sources are welcome via GitHub.
- github.com/builderw33/SR17.org
- Open an issue for tips, corrections, or source suggestions.
- Open a pull request to propose edits to a specific section.
- Contributors agree to disclose any financial or professional relationship to opioid manufacturers, marketers, or treatment providers. Disclosures are published with the contribution.
- Community-submitted content is reviewed against the editorial principles above before publication.
For deeper detail on how we research and source content, see the editorial methodology page.